Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
Read SourceA recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
Read SourceFor press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE